These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

137 related items for PubMed ID: 17883882

  • 1. Patient compliance with alendronate, risedronate and raloxifene for the treatment of osteoporosis in postmenopausal women.
    Ringe JD, Christodoulakos GE, Mellström D, Petto H, Nickelsen T, Marín F, Pavo I.
    Curr Med Res Opin; 2007 Nov; 23(11):2677-87. PubMed ID: 17883882
    [Abstract] [Full Text] [Related]

  • 2. Compliance and satisfaction with raloxifene versus alendronate for the treatment of postmenopausal osteoporosis in clinical practice: An open-label, prospective, nonrandomized, observational study.
    Turbí C, Herrero-Beaumont G, Acebes JC, Torrijos A, Graña J, Miguélez R, Sacristán J, Marín F.
    Clin Ther; 2004 Feb; 26(2):245-56. PubMed ID: 15038947
    [Abstract] [Full Text] [Related]

  • 3. Comparison of raloxifene and bisphosphonates based on adherence and treatment satisfaction in postmenopausal Asian women.
    Pasion EG, Sivananthan SK, Kung AW, Chen SH, Chen YJ, Mirasol R, Tay BK, Shah GA, Khan MA, Tam F, Hall BJ, Thiebaud D.
    J Bone Miner Metab; 2007 Feb; 25(2):105-13. PubMed ID: 17323180
    [Abstract] [Full Text] [Related]

  • 4. Response to therapy with once-weekly alendronate 70 mg compared to once-weekly risedronate 35 mg in the treatment of postmenopausal osteoporosis.
    Sebba AI, Bonnick SL, Kagan R, Thompson DE, Skalky CS, Chen E, de Papp AE, Fosamax Actonel Comparison Trial investigators.
    Curr Med Res Opin; 2004 Dec; 20(12):2031-41. PubMed ID: 15706659
    [Abstract] [Full Text] [Related]

  • 5. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis.
    Cramer JA, Amonkar MM, Hebborn A, Altman R.
    Curr Med Res Opin; 2005 Sep; 21(9):1453-60. PubMed ID: 16197664
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Role of alendronate and risedronate in preventing and treating osteoporosis.
    Peters ML, Leonard M, Licata AA.
    Cleve Clin J Med; 2001 Nov; 68(11):945-51. PubMed ID: 11718433
    [Abstract] [Full Text] [Related]

  • 8. Modulation of bone turnover in orchidectomized rats treated with raloxifene and risedronate.
    Khedr NF, El-Ashmawy NE, El-Bahrawy HA, Haggag AA, El-Abd EE.
    Fundam Clin Pharmacol; 2013 Oct; 27(5):526-34. PubMed ID: 22762129
    [Abstract] [Full Text] [Related]

  • 9. Gaps in treatment among users of osteoporosis medications: the dynamics of noncompliance.
    Brookhart MA, Avorn J, Katz JN, Finkelstein JS, Arnold M, Polinski JM, Patrick AR, Mogun H, Solmon DH.
    Am J Med; 2007 Mar; 120(3):251-6. PubMed ID: 17349448
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Health-economic comparison of three recommended drugs for the treatment of osteoporosis.
    Brecht JG, Kruse HP, Möhrke W, Oestreich A, Huppertz E.
    Int J Clin Pharmacol Res; 2004 Mar; 24(1):1-10. PubMed ID: 15575171
    [Abstract] [Full Text] [Related]

  • 12. [Osteoporosis].
    Bartl R.
    Internist (Berl); 2002 Dec; 43(12):1529-30, 1533-43. PubMed ID: 12607392
    [No Abstract] [Full Text] [Related]

  • 13. Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis.
    Penning-van Beest FJ, Goettsch WG, Erkens JA, Herings RM.
    Clin Ther; 2006 Feb; 28(2):236-42. PubMed ID: 16678644
    [Abstract] [Full Text] [Related]

  • 14. Gastrointestinal tolerability and patterns of switching in patients treated for primary osteoporosis: the Swedish Adherence Register Analysis (SARA).
    Landfeldt E, Lang A, Robbins S, Ström O.
    Calcif Tissue Int; 2011 Sep; 89(3):234-45. PubMed ID: 21695544
    [Abstract] [Full Text] [Related]

  • 15. Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study.
    Rosen CJ, Hochberg MC, Bonnick SL, McClung M, Miller P, Broy S, Kagan R, Chen E, Petruschke RA, Thompson DE, de Papp AE, Fosamax Actonel Comparison Trial Investigators.
    J Bone Miner Res; 2005 Jan; 20(1):141-51. PubMed ID: 15619680
    [Abstract] [Full Text] [Related]

  • 16. Comparison of risedronate to alendronate and calcitonin for early reduction of nonvertebral fracture risk: results from a managed care administrative claims database.
    Watts NB, Worley K, Solis A, Doyle J, Sheer R.
    J Manag Care Pharm; 2004 Jan; 10(2):142-51. PubMed ID: 15032563
    [Abstract] [Full Text] [Related]

  • 17. Efficacy, side effects and route of administration are more important than frequency of dosing of anti-osteoporosis treatments in determining patient adherence: a critical review of published articles from 1970 to 2009.
    Lee S, Glendenning P, Inderjeeth CA.
    Osteoporos Int; 2011 Mar; 22(3):741-53. PubMed ID: 20589368
    [Abstract] [Full Text] [Related]

  • 18. Determinants of non-compliance with bisphosphonates in women with postmenopausal osteoporosis.
    Penning-van Beest FJ, Erkens JA, Olson M, Herings RM.
    Curr Med Res Opin; 2008 May; 24(5):1337-44. PubMed ID: 18380910
    [Abstract] [Full Text] [Related]

  • 19. Tolerability of risedronate in postmenopausal women intolerant of alendronate.
    Adachi JD, Adami S, Miller PD, Olszynski WP, Kendler DL, Silverman SL, Licata AA, Li Z, Gomez-Panzani E.
    Aging (Milano); 2001 Oct; 13(5):347-54. PubMed ID: 11820707
    [Abstract] [Full Text] [Related]

  • 20. Adherence and persistence associated with the pharmacologic treatment of osteoporosis in a managed care setting.
    Downey TW, Foltz SH, Boccuzzi SJ, Omar MA, Kahler KH.
    South Med J; 2006 Jun; 99(6):570-5. PubMed ID: 16800411
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.